ERDERA Clinical Trial Call – Call Text

1:1
Call text draft setting out rules, eligibility and staged application process for the ERDERA Clinical Trial Call 2026.

Call text draft for the ERDERA Clinical Trial Call, describing governance, scope (in scope/out of scope), funding mechanism, eligibility criteria, application stages (including Stage 0 Expression of Interest and Stage 1 Short Proposal), evaluation, and annexed definitions and indicative timeline. It includes submission deadlines for Expressions of Interest (10 September 2026) and Short Proposals (29 October 2026) and provides a contact email for the Scientific Secretariat.

Version 3.0 | 1st July 2026

This call text may be subject to minor revisions. Applicants are responsible for regularly verifying that they are consulting the latest available version.

blank

publication

Year of publication

2026

Source

European Rare Diseases Research Alliance (ERDERA)

Author

You might also be interested in

July 24 @ 3:00 pm - 4:00 pm
This webinar will present a theoretical framework for situating ethics across research activities. The framework will then be brought to life through a relevant case study discussion, giving participants a concrete reference point for the episodes ahead.
This 2026 country report outlines the policy, research, care and support landscape for rare diseases in Poland.
Held in Riga on 9–10 June, the workshop brought National Mirror Group experts, researchers, clinicians and policymakers together to exchange practical lessons on how national rare disease registries can better support research and alignment across countries.
ERDERA (the European Rare Diseases Research Alliance) has opened its Clinical Trial Call to support multinational early-phase clinical trials in rare diseases. The call will fund studies designed to generate robust clinical evidence, strengthen regulatory readiness and make rare disease trials more feasible across countries.